[{"orgOrder":0,"company":"Open Book Extracts","sponsor":"Biopharmaceutical Research Company","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Open Book Extracts","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Open Book Extracts \/ Biopharmaceutical Research Company","highestDevelopmentStatusID":"1","companyTruncated":"Open Book Extracts \/ Biopharmaceutical Research Company"}]

Find Clinical Drug Pipeline Developments & Deals by Open Book Extracts

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The partnership with BRC, supports the study of Delta-9 THC products and formulations, allowing OBX to identify the phase appropriate, optimal products for formulations including Delta-9-tetrahydrocannabinol.

                          Brand Name : Delta-9 THC

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 14, 2022

                          Lead Product(s) : Tetrahydrocannabinol

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Sponsor : Biopharmaceutical Research Company

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank